A similar situation has also been reported in breast cancer and other carcinomas, and this may contribute to the insufficient and heterogeneous expression of checkpoint molecules 17 and may be influenced by age, tumor size, histologic grade, nodal metastasis, hormone receptor status, HER2 status, and the extent of TILs 43, 44. This evidence concerns the gene ERBB2 and breast cancer.